Tanım

Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. StratejiHelix'e göre, the intravenous immunoglobulin market in United States is expected to increase by US$ 2.5 billion during 2022-2028, expanding at a CAGR of 6.4% tahmin dönemi boyunca.

Rapor, döneme ilişkin güncel pazar büyüklüğü verilerini sağlar 2018-2021 ve tahmin 2028 covering key market aspects like sales value for intravenous immunoglobulin. The United States intravenous immunoglobulin market is segmented on the basis of application, and end user. Based on application, the intravenous immunoglobulin market in United States is categorized into chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, others. The immunodeficiency diseases segment held the largest share of the United States intravenous immunoglobulin market in 2021 ve tahmin dönemi boyunca payını koruması bekleniyor. On the basis of end user, the intravenous immunoglobulin market in United States has been segmented into homecare, hospitals & clinics.

The United States intravenous immunoglobulin market is highly competitive. Key companies profiled in the report include ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited. Competitive landscape gives a description of the competitive nature of the intravenous immunoglobulin market in United States and a description of the leading companies. Son yıllarda piyasayı şekillendiren önemli finansal anlaşmalar belirlendi.

Rapor, bu sektörde faaliyet gösteren şirket ve kuruluşlar için paha biçilmez bir kaynaktır. It provides a cohesive picture of the intravenous immunoglobulin market to help drive informed decision making for industry executives, kural koyucular, akademik, ve analistler.

Rapor Kapsamı

Başvuru: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, others
End user: homecare, hospitals & clinics
Dikkate alınan yıllar: bu rapor dönemi kapsamaktadır 2018 ile 2028
Adı geçen şirket: ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited

Paydaşlar için Temel Faydalar

– Get a comprehensive picture of the United States intravenous immunoglobulin market
– Yerel verilere dayanarak bölgesel stratejiler ve stratejik önceliklerin belirlenmesi
– Büyüme sektörlerini ve yatırım eğilimlerini belirleyin

İçindekiler

Parça 1. giriiş
– Çalışmanın kapsamı
– Çalışma periyodu
– Coğrafik kapsam
– Araştırma metodolojisi
Parça 2. Intravenous immunoglobulin market overview
Parça 3. Market breakdown by application
– Chronic inflammatory demyelinating polyneuropathy (CIDP)
– Chronic lymphocytic leukemia
– Congenital HIV/AIDS
– Guillain-barre syndrome (GBS)
– Hypogammaglobulinemia
– Immune thrombocytopenic purpura (ITP)
– Immunodeficiency diseases
– Kawasaki disease
– Multifocal motor neuropathy (MMN)
– Myasthenia gravis
– Diğerleri
Parça 4. Market breakdown by end user
– Homecare
– Hastaneler & clinics
Parça 5. Anahtar şirketler
– ADMA Biologics Inc.
– Biotest AG
– CSL Limited
– Grifols, S.A.
– Johnson & Johnson
– Kedrion Biopharma Inc. (Kedrion SpA)
– LFB S.A.
– Octapharma AG
– Takeda Pharmaceutical Company Limited
StratejiHelix Hakkında
Sorumluluk reddi beyanı